Clinical Research Directory
Browse clinical research sites, groups, and studies.
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Sponsor: University of Texas at Austin
Summary
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.
Key Details
Gender
All
Age Range
55 Years - Any
Study Type
INTERVENTIONAL
Enrollment
156
Start Date
2017-07-01
Completion Date
2023-03-31
Last Updated
2022-05-18
Healthy Volunteers
No
Conditions
Interventions
Gabapentin Enacarbil
1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
Placebo Oral Tablet
1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
Locations (1)
The University of Texas at Austin
Austin, Texas, United States